106 related articles for article (PubMed ID: 698971)
1. Some comments on the necessity of receptor determination in human breast cancer.
Jonat W; Maass H
Cancer Res; 1978 Nov; 38(11 Pt 2):4305-6. PubMed ID: 698971
[TBL] [Abstract][Full Text] [Related]
2. Clinical correlations of steroid receptors and male breast cancer.
Everson RB; Lippman ME; Thompson EB; McGuire WL; Wittliff JL; De Sombre ER; Jensen EV; Singhakowinta A; Brooks SC; Neifeld JP
Cancer Res; 1980 Apr; 40(4):991-7. PubMed ID: 7357565
[TBL] [Abstract][Full Text] [Related]
3. Steroid receptors in breast cancer.
Desombre ER
Monogr Pathol; 1984; (25):149-74. PubMed ID: 6377047
[TBL] [Abstract][Full Text] [Related]
4. Role of pituitary hormones in the growth of human breast cancer.
Pearson OH; Manni A; Chambers M; Brodkey J; Marshall JS
Cancer Res; 1978 Nov; 38(11 Pt 2):4323-6. PubMed ID: 212192
[TBL] [Abstract][Full Text] [Related]
5. Automated quantitation of immunocytochemically localized estrogen receptors in human breast cancer.
McClelland RA; Finlay P; Walker KJ; Nicholson D; Robertson JF; Blamey RW; Nicholson RI
Cancer Res; 1990 Jun; 50(12):3545-50. PubMed ID: 2187598
[TBL] [Abstract][Full Text] [Related]
6. Biologic and clinical characteristics of breast cancer with single hormone receptor positive phenotype.
Rakha EA; El-Sayed ME; Green AR; Paish EC; Powe DG; Gee J; Nicholson RI; Lee AH; Robertson JF; Ellis IO
J Clin Oncol; 2007 Oct; 25(30):4772-8. PubMed ID: 17876012
[TBL] [Abstract][Full Text] [Related]
7. Steroid receptors in human breast cancer.
McGuire WL
Cancer Res; 1978 Nov; 38(11 Pt 2):4289-91. PubMed ID: 698967
[TBL] [Abstract][Full Text] [Related]
8. The NFkappaB pathway and endocrine-resistant breast cancer.
Zhou Y; Eppenberger-Castori S; Eppenberger U; Benz CC
Endocr Relat Cancer; 2005 Jul; 12 Suppl 1():S37-46. PubMed ID: 16113098
[TBL] [Abstract][Full Text] [Related]
9. Hormone receptors and Japanese breast cancer.
Matsumoto K; Kitamura Y; Sugano H
Acta Pathol Jpn; 1982; 32 Suppl 1():145-54. PubMed ID: 6764994
[TBL] [Abstract][Full Text] [Related]
10. Content of epidermal growth factor receptor in metastatic breast cancer: its role in endocrine sensitivity prediction.
Nesković-Konstantinović ZB; Nikolić-Vukosavljević DB; Branković-Magić MV; Mitrovic LB; Spuzić I
Neoplasma; 2000; 47(2):107-13. PubMed ID: 10985476
[TBL] [Abstract][Full Text] [Related]
11. [Place of hormone receptor determination in the therapeutic strategy of breast cancer].
Clavel B; Gest J
Pathol Biol (Paris); 1983 Dec; 31(10):809-18. PubMed ID: 6366702
[TBL] [Abstract][Full Text] [Related]
12. Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors--International Breast Cancer Study Group.
Viale G; Regan MM; Maiorano E; Mastropasqua MG; Golouh R; Perin T; Brown RW; Kovács A; Pillay K; Ohlschlegel C; Braye S; Grigolato P; Rusca T; Gelber RD; Castiglione-Gertsch M; Price KN; Goldhirsch A; Gusterson BA; Coates AS
J Clin Oncol; 2008 Mar; 26(9):1404-10. PubMed ID: 18349391
[TBL] [Abstract][Full Text] [Related]
13. Microtubule-associated protein-tau is a bifunctional predictor of endocrine sensitivity and chemotherapy resistance in estrogen receptor-positive breast cancer.
Andre F; Hatzis C; Anderson K; Sotiriou C; Mazouni C; Mejia J; Wang B; Hortobagyi GN; Symmans WF; Pusztai L
Clin Cancer Res; 2007 Apr; 13(7):2061-7. PubMed ID: 17404087
[TBL] [Abstract][Full Text] [Related]
14. Modulation of molecular marker expression by induction chemotherapy in locally advanced breast cancer: correlation with the response to therapy and the expression of MDR1 and LRP.
Schneider J; Lucas R; Sánchez J; Ruibal A; Tejerina A; Martín M
Anticancer Res; 2000; 20(6B):4373-7. PubMed ID: 11205274
[TBL] [Abstract][Full Text] [Related]
15. Re-evaluating adjuvant breast cancer trials: assessing hormone receptor status by immunohistochemical versus extraction assays.
Regan MM; Viale G; Mastropasqua MG; Maiorano E; Golouh R; Carbone A; Brown B; Suurküla M; Langman G; Mazzucchelli L; Braye S; Grigolato P; Gelber RD; Castiglione-Gertsch M; Price KN; Coates AS; Goldhirsch A; Gusterson B;
J Natl Cancer Inst; 2006 Nov; 98(21):1571-81. PubMed ID: 17077359
[TBL] [Abstract][Full Text] [Related]
16. Selective reduction of estrogen receptor (ER) positive breast cancer occurrence by estrogen receptor modulators supports etiological distinction between ER positive and ER negative breast cancers.
Kurbel S
Med Hypotheses; 2005; 64(6):1182-7. PubMed ID: 15823713
[TBL] [Abstract][Full Text] [Related]
17. An association between steroid hormone receptors and response to cytotoxic chemotherapy in patients with metastatic breast cancer.
Allegra JC; Lippman ME; Thompson EB; Simon R
Cancer Res; 1978 Nov; 38(11 Pt 2):4299-304. PubMed ID: 698970
[No Abstract] [Full Text] [Related]
18. [Steroid receptors and breast carcinoma].
Pasić R; Dulbegović B; Softić D; Wittlif JL
Med Pregl; 1991; 44(1-2):48-51. PubMed ID: 1870463
[TBL] [Abstract][Full Text] [Related]
19. Biologic basis of sequential and combination therapies for hormone-responsive breast cancer.
Pietras RJ
Oncologist; 2006; 11(7):704-17. PubMed ID: 16880230
[TBL] [Abstract][Full Text] [Related]
20. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes.
Carey LA; Dees EC; Sawyer L; Gatti L; Moore DT; Collichio F; Ollila DW; Sartor CI; Graham ML; Perou CM
Clin Cancer Res; 2007 Apr; 13(8):2329-34. PubMed ID: 17438091
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
